Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Tebentafusp in MRD Melanoma

 

TebeMRD

Full Title

A Phase II Non-Randomized, Open-label, Multi-centre Study of the Safety and Efficacy of Tebentafusp in Melanoma with Molecular Relapsed Disease

Chief Investigator: Prof. Mark Middleton

Sponsor: University of Oxford

 

STATUS

Protocol currently under development.